AmoyDx® Pan Lung Cancer PCR Panel application for approval in Japan as a Primary Companion Diagnostic for Taletrectinib

tikeda3
Mar 28
1 min read

TOKYO and XIAMEN, March 27, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that they have submitted a partial change application to the MHLW (Ministry of Health, Labour and Welfare) for the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic (CDx) for Taletrectinib in Japan.

Read the full release here:

Recent Posts

See All

AmoyDx® Pan Lung Cancer PCR Panel application for approval in Japan as a Companion Diagnostic for LORBRENA ® Lorlatinib

TOKYO and XIAMEN, February 6th, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co.,...

NCC to initiate new research to develop nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), supported by PREMIA and Paradigm, to further accelerate precision medicine for patients.

The National Cancer Center (“NCC”), Precision Medicine Asia Co., Ltd. (“PREMIA”) and Paradigm Health Inc (“Paradigm”), announced the...

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnosticfor AUGTYRO® (repotrectinib)

TOKYO and XIAMEN, September 25th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia...